Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study

[1]  Deepa S. Subramaniam,et al.  Management of Brain Metastases in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer , 2018, Front. Oncol..

[2]  Ying Cheng,et al.  Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[3]  J. Shih,et al.  Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib. , 2017, The oncologist.

[4]  P. Brown,et al.  Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA) , 2017, JAMA oncology.

[5]  Zhimin Zhang,et al.  Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study , 2017, BMC Cancer.

[6]  L. Sequist,et al.  Marked Differences in CNS Activity among EGFR Inhibitors: Case Report and Mini-Review. , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[7]  T. Mitsudomi,et al.  Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy , 2016, Cancer science.

[8]  L. Sequist,et al.  First‐Line Afatinib versus Chemotherapy in Patients with Non–Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9]  F. Hirsch,et al.  Hepatic Metastases is Associated with Poor Efficacy of Erlotinib as 2nd/3rd Line Therapy in Patients with Lung Adenocarcinoma , 2016, Medical science monitor : international medical journal of experimental and clinical research.

[10]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[11]  L. Crinò,et al.  Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer , 2015, Expert opinion on pharmacotherapy.

[12]  L. Sequist,et al.  Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. , 2015, The Lancet. Oncology.

[13]  V. Torri,et al.  Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations. , 2015, Critical reviews in oncology/hematology.

[14]  L. Sequist,et al.  Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. , 2015, The Lancet. Oncology.

[15]  R. Wiewrodt,et al.  Efficacy of the Irreversible ErbB Family Blocker Afatinib in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)–Pretreated Non–Small-Cell Lung Cancer Patients with Brain Metastases or Leptomeningeal Disease , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[16]  G. Lopes,et al.  Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[17]  Yi-long Wu,et al.  Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. , 2014, The Lancet. Oncology.

[18]  Koichi Hagiwara,et al.  Effectiveness of Gefitinib against Non–Small-Cell Lung Cancer with the Uncommon EGFR Mutations G719X and L861Q , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[19]  Yi-long Wu,et al.  Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803). , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  Joe Y. Chang,et al.  Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Dae-Ho Lee,et al.  Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. , 2012, Lung Cancer.

[22]  Young Hak Kim,et al.  Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer , 2012, Cancer Chemotherapy and Pharmacology.

[23]  Xianghua Luo,et al.  Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  F. Barlesi,et al.  Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01). , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  Jun Ma,et al.  Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.

[26]  J. Shih,et al.  Effectiveness of Tyrosine Kinase Inhibitors on “Uncommon” Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non–Small Cell Lung Cancer , 2011, Clinical Cancer Research.

[27]  R. Talamini,et al.  Activity of Pemetrexed on brain metastases from Non-Small Cell Lung Cancer. , 2010, Lung cancer.

[28]  J. Abbruzzese,et al.  F1000 highlights , 2009, JAMA.

[29]  Shenglin Ma,et al.  Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population. , 2009, Lung cancer.

[30]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[31]  M. Rinaldi,et al.  Up‐front chemotherapy and radiation treatment in newly diagnosed nonsmall cell lung cancer with brain metastases , 2007, Cancer.

[32]  S. Digumarthy,et al.  Does Initial Staging or Tumor Histology Better Identify Asymptomatic Brain Metastases in Patients with Non–small Cell Lung Cancer? , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[33]  T. Kijima,et al.  Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases. , 2004, Clinical lung cancer.

[34]  L Gaspar,et al.  Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. , 1997, International journal of radiation oncology, biology, physics.

[35]  H. Hansen,et al.  Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Jing Wu,et al.  The concentration of erlotinib in the cerebrospinal fluid of patients with brain metastasis from non-small-cell lung cancer. , 2014, Molecular and clinical oncology.

[37]  V. Guillem,et al.  responding The , 2010 .

[38]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.